RxDoctor Payments Data

Irshad Hussain, MD

Internal Medicine · Ashland, MSNPI 1922047729

Payments from drug & device makers

$753in general payments, 2019–2025

Across 43 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$166
  • GSK$151
  • Novartis$87
  • AbbVie$75
  • Boehringer Ingelheim$45
  • Amgen$43
  • plus $187 from 10 others

What the payments were for

  • Food & beverage$753100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$753 in reported general payments places this provider in the 55th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$86,201
Medicare patients
2,396
Services billed
5,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide276$439,576
JardianceEmpagliflozin198$275,711
Trelegy ElliptaFluticasone/Umeclidin/Vilanter111$149,841
MounjaroTirzepatide119$143,852
TrulicityDulaglutide121$142,712
EliquisApixaban131$141,705
Tresiba Flextouch U-100Insulin Degludec64$85,293
XareltoRivaroxaban64$84,765
LinzessLinaclotide92$82,523
TradjentaLinagliptin53$71,295
FarxigaDapagliflozin Propanediol47$65,334
EntrestoSacubitril/Valsartan38$49,884
Novolog FlexpenInsulin Aspart114$46,722
Tresiba Flextouch U-200Insulin Degludec23$45,123
VascepaIcosapent Ethyl52$34,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$45$374,802267 claims
GSKTrelegy Ellipta, Breo Ellipta$151$166,357128 claims
PfizerEliquis$27$141,705131 claims
AbbVieLinzess, Restasis$75$97,372115 claims
AstraZenecaFarxiga$32$65,33447 claims
NovartisEntresto$87$49,88438 claims
Sumitomo Pharma America, Inc.Gemtesa$19$18,19321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Ashland

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →